Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jun 7, 2018No Imminent Plan to Effect Reverse Stock SplitPulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that each of the following...
- May 17, 2018Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San DiegoCompany will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018...
- May 11, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter with the initiation of dosing in our phase 1/1b...
- Mar 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is...
- Mar 13, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The Company...
- Feb 12, 2018Phase 1 data is expected in mid-2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose...
- Jan 24, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new...
- Jan 22, 2018Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received...
Nov 9, 2017Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of PulmazolePulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter financial results and provided an overview of recent operational highlights. "During the third quarter, we made significant progress...
Oct 31, 2017Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstreamPulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it will present...
Oct 30, 2017Dr. Roach will help Pulmatrix accelerate the development of its innovative inhaled drugsPulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has appointed...
Oct 3, 2017The FDA designation provides five years of market exclusivity for Pulmatrix's inhaled product for treating fungal infections in the lungs of patients with allergic bronchopulmonary aspergillosisPulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
- Sep 21, 2017
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 2:15 PM EDT in the Intercontinental New York Barclay Hotel in...
- Sep 20, 2017The patents broaden the protection and potential applications for Pulmatrix's innovative inhaled drug delivery platform and most advanced drug candidate
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two...
- Sep 8, 2017
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 10:25 AM EDT in the Lotte New York Palace Hotel in New...
- Sep 6, 2017The agreement will accelerate the development of the innovative inhaled drug
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has partnered with...
- Sep 5, 2017The Award Supports Advancement of PUR1900 to Phase 1/1B Clinical Trial in 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received an...
- Aug 4, 2017Strengthened Board of Directors and Completed In-License Agreement
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provided an overview of recent operational highlights. "During the second quarter, we further strengthened our...
-
Jun 15, 2017Mr. Munshi brings over 25 years of executive leadership experience in biotechnology and pharmaceuticals to help Pulmatrix move through the next stage of company development.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs for major lung diseases, has announced the appointment of Amit D. Munshi to the Pulmatrix Board of...
- Jun 13, 2017The novel compounds target an enzyme involved in both inflammation and cancer, and may offer a new approach for treating respiratory diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
-
Jun 9, 2017
NASDAQ:PULM Pulmatrix (NASDAQ:PULM) is a Lexington, MA based clinical stage biopharmaceutical company developing innovative inhaled products to address unmet medical needs in serious pulmonary...
- May 9, 2017The patent gives Pulmatrix intellectual property protection for the drug until 2033
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key...
- May 5, 2017
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results. "During the first quarter, we continued to make progress across our iSPERSE-based development pipeline of inhaled...
- May 3, 2017- Will Develop and Execute Commercial and Business Development Strategies -
Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biotechnology company developing inhaled therapies for the treatment of significant unmet needs in respiratory diseases, today announced the...
- Mar 27, 2017The world-leading experts will help accelerate the development of PUR1900, Pulmatrix's innovative inhaled drug for fungal infections in the lungs
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has added two...
- Mar 21, 2017The patent extends Pulmatrix's broad protection for its innovative technology to Europe
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key...
Mar 10, 2017Pulmatrix, Inc. (NASDAQ: PULM) today announces 2016 financial results, reviews the Company's recent progress, and provides an outlook for 2017 for its pulmonary disease development pipeline. "The...
- Feb 3, 2017
Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
- Jan 30, 2017
Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
- Jan 17, 2017The FDA designation adds five years of market exclusivity for Pulmatrix' inhaled product for treating fungal infections in the lungs of CF patients
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
- Dec 19, 2016The patents significantly broaden protection for the technology--and for its use to treat a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received five...
- Nov 29, 2016In wide-ranging interview, Hava discusses advances in treating respiratory diseases using inhaled drugs, among other topics
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its Chief Scientific...
- Nov 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced it third quarter financial...
- Oct 11, 2016New study shows that Pulmatrix's inhaled drug delivery platform successfully delivers higher doses of an antifungal drug to the lungs compared to oral delivery.
Pulmatrix, Inc. (NASDAQ: PULM) will present promising new preclinical data about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference. "The preclinical...
- Oct 3, 2016Dr. Sherman's extensive experience in developing drugs in oncology and other therapeutic areas will help Pulmatrix target more diseases, potentially including cancer.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, announced today that the company has appointed Matthew L. Sherman, M.D., Executive Vice President and...
- Sep 23, 2016Recent white paper by Envigo explains the advantages of delivering drugs to the lungs--and describes how this delivery method is increasingly being used for a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM) today announced that a recent white paper, What is the future of inhalation delivery?, by global research and consulting firm Envigo predicts rapid growth for drugs...
- Sep 7, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will give a presentation at the 2016 Aegis Growth Conference at The Encore at Wynn Las Vegas in Nevada on Wednesday, September 21, 2016 at 10:00 AM PDT. Pulmatrix...
- Aug 31, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 5:30 PM EDT in the Lotte New York Palace Hotel in New...
- Aug 17, 2016The designation by the FDA is based on the hypothesis that Pulmatrix's drug may be superior to existing treatments. It creates a quicker regulatory path to market while also providing financial incentives.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that the U.S. Food & Drug Administration has granted the company's request for orphan drug status for its inhaled drug for treating pulmonary fungal...
- Aug 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline. "In the first half of the year, we...
- Jul 19, 2016Data Support Continued Development Towards Pivotal Bioequivalence Program for European Registration
Pulmatrix, Inc. (NASDAQ: PULM), today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a...
- Jul 6, 2016In an interview with News Medical, Pulmatrix CEO Robert Clarke explains how innovative dry powders enable drugs to be delivered to the lungs more efficiently
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled...
- Jun 27, 2016
Pulmatrix, Inc., (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness...
- Jun 24, 2016Inclusion in the index will bring greater shareholder awareness of Pulmatrix's progress in developing novel inhaled drugs
Pulmatrix, Inc., (NASDAQ: PULM), a specialty pharmaceutical company developing innovative inhaled drugs, announced today that it was added to the Russell Microcap Index when Russell Investments...
- May 25, 2016PUR0200, a once-daily long acting muscarinic antagonist bronchodilator formulation, was given to healthy volunteers to measure pharmacokinetics and to test for safety.
Pulmatrix (NASDAQ:PULM), a specialty pharmaceutical company developing novel inhaled therapeutic formulations based on the company's proprietary iSPERSE™ technology, has completed a pilot...
- May 24, 2016
Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its...
- May 5, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results and provides an update on the progress of its drug development pipeline. "During the first quarter, we continued to...
- Apr 19, 2016Writing in ONdrugDelivery Magazine, CSO David L. Hava describes how innovative new strategies for delivering inhaled drugs to the lungs can fight serious bacterial and fungal infections.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to...
- Mar 10, 20162015 was a transformational year - lead assets for COPD and cystic fibrosis continue to progress in clinical development.
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Company's recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline. "2015...
-
Mar 10, 2016
Dear Fellow Shareholders, Continuing our Momentum As Pulmatrix moves into 2016, we wanted to describe to our shareholders the significant progress the Company is making—and how...
- Mar 4, 2016CEO Clarke to provide update on PULM business activities
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of...
-
Feb 16, 2016
Capsugel and Pulmatrix, Inc. ("Pulmatrix") (NASDAQ: PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel...
-
Feb 1, 2016
Pulmatrix, Inc. (NASDAQ: PULM) reports that enrollment is underway in the Company's European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily...
-
Jan 7, 2016
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at Biotech Showcase 2016 on Monday, January 11th at 2:30 pm PST (5:30 pm EST). A live webcast of the presentation may be accessed in...
-
Dec 22, 2015
What: Pulmatrix, Inc. (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
-
Dec 18, 2015
Pulmatrix, Inc. (Nasdaq: PULM) announced that the Company's common stock has qualified for and will begin trading today on the Nasdaq Global Market. The trading symbol remains PULM. Prior to...
-
Dec 8, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of...
-
Nov 12, 2015
Pulmatrix, Inc. (NASDAQ: PULM) reports third quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. Since the beginning of...
- Oct 9, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences. Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth...
-
Oct 8, 2015Data to be Presented at 2015 North American Cystic Fibrosis Conference
Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for...
-
Oct 1, 2015
Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million...
- Sep 23, 2015- Results to be Presented September 29th at 2015 European Respiratory Society Congress -
Pulmatrix, Inc. (NASDAQ: PULM) will report data from a Phase 1B study evaluating PUR0200, an iSPERSE formulation of a long acting muscarinic antagonist (LAMA) bronchodilator, on September 29th at...
-
Sep 11, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data...
- Sep 3, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 11:40 am EDT. As part of the presentation, Robert...
-
Sep 2, 2015
Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company's underlying iSPERSE™ inhaled dry powder technology. The patent broadly covers small, dense and dispersible...
- Aug 14, 2015
Pulmatrix, Inc., (NASDAQ: PULM) reports second quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. "During the second...
-
Jul 29, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will webcast an investor presentation August 6, 2015 at 10:45 am EDT. As part of the presentation, Robert Clarke, Chief Executive Officer, will review Pulmatrix's...
- Jul 23, 2015
Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter...
-
Jul 10, 2015
Dear Fellow Shareholders, The Pulmatrix management team and I would like to thank our founding institutional shareholders for their continued support and investment. Additionally, we want to...
- Jun 25, 2015
Pulmatrix, Inc. (NASDAQ: PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc., a company...
- Jun 18, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced the appointment of Michael...
-
Jun 16, 2015
Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S....
- Jun 16, 2015PUR1900 is Lead Product Candidate in Company's Proprietary Pipeline Focused on Rare Pulmonary Diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an...
- Jun 16, 2015Pulmatrix, Inc. now has $27 million in cash and cash equivalents
Pulmatrix, Inc., (NASDAQ: PULM), previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private...
-
Mar 16, 2015
Santa Rosa, Ca., March --- March 16, 2015 – Ruthigen, Inc. (NASDAQ: RTGN) (“Ruthigen”), and Pulmatrix, Inc., (“Pulmatrix”), a Lexington, Massachusetts based clinical stage...
-
May 5, 2014Results Demonstrated the Enablement of High Drug Load Delivery with iSPERSE Dry Powder Delivery Technology
Lexington, MA, May 5, 2014 – Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on...
-
May 5, 2014Clinical Results Highlight Advantages of the iSPERSE Inhaled Dry Powder Delivery Platform over Conventional Lactose Blend Technologies
Lexington, MA, May 5, 2014 – Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive...
